The injectable presentation of ferric derisomaltose is handled as a high-dose intravenous iron substitute. The concentrate delivers 100 mg elemental iron per mL. Dilution is made in 0.9% sodium chloride injection or 5% glucose injection, with the final volume determined by body weight and haemoglobin deficit according to the approved prescribing information. The iron–derisomaltose complex is a dark brown colloidal solution with a narrow molecular weight distribution relative to low molecular weight iron dextran. Release testing for visible particulate matter follows USP <790> and Ph. Eur. 2.9.20; sub-visible particle counts are controlled under USP <788> and Ph. Eur. 2.9.19. The concentrate is filled into Type I borosilicate glass vials sealed with chlorobutyl elastomeric closures qualified under USP <381> and ISO 8362-1. Terminal sterilisation is performed by moist heat, typically at 121°C with an F₀ not less than 15 minutes. The finished injectable product is stored at 15–25°C and protected from light. In infusion sets, 0.9% sodium chloride is used because prolonged admixture hold times in glucose-containing fluids can produce low-level interactions with iron carbohydrate colloids. No mixing with other medicinal products is permitted unless compatibility has been demonstrated under the approved product information.

Why Does Terminal Heat Sterilisation Influence Ferric Derisomaltose Colloidal Stability in Glass Vials?

Because terminal sterilisation applies moist heat to the filled vial, the iron–derisomaltose complex is exposed to thermal stress that can shift pH, increase free iron, and promote particle aggregation if the load is not controlled. The formulation pH is maintained between 5.0 and 7.0; drift above 7.0 during sterilisation can destabilise the colloidal iron hydroxide core. Vials are Type I borosilicate glass with chlorobutyl elastomeric closures qualified under USP <381> and ISO 8362-1. Steam autoclave cycles are validated with heat penetration probes placed in the coldest vial location and biological indicators containing Geobacillus stearothermophilus spores at not less than 10⁶ per indicator. The slowest vial reaches 121°C for a hold time sufficient to achieve an F₀ not less than 15 minutes. Autoclave load size and tray spacing are fixed in the validation protocol because overloading produces cold spots. After sterilisation, sub-visible particle testing is repeated under USP <788> and Ph. Eur. 2.9.19 because heat and closure contact can generate particles ≥ 10 µm. Closure integrity is verified by dye ingress or vacuum decay after sterilisation. Terminal sterilisation is preferred over aseptic filtration when the product format permits; this reduces sterility assurance risk and avoids filter retention of the colloidal active fraction. The container closure system is sealed to prevent moisture ingress during storage at 15–25°C.

Published data for ferric derisomaltose tablet formulations are limited; the processing conditions below are derived from the behaviour of high molecular weight iron carbohydrate complexes and require confirmation by formal design-of-experiment studies under ICH Q8. Direct compression is used when the API fraction is 30–45% w/w in microcrystalline cellulose with pregelatinized starch as the disintegrant. Crospovidone is added at 2–5% w/w and colloidal silicon dioxide at 0.5–1.0% w/w to improve flow. Blending in a bin blender proceeds until iron content uniformity shows a relative standard deviation not greater than 5% by USP <905> sampling. Magnesium stearate is added at 0.5–1.0% w/w and mixed for not more than 5 minutes; longer lubrication reduces tablet breaking force. Compression is performed on a rotary tablet press with precompression force 5–8 kN and main compression force 12–20 kN. Tablet breaking force is measured per USP <1217> and controlled at 80–120 N. Disintegration is tested by USP <701> in purified water at 37°C; uncoated tablets should disintegrate within 30 minutes. Dissolution testing is conducted under USP <711>; however, no harmonised ferric derisomaltose oral dissolution monograph exists. Oral absorption of ferric iron from the complex requires reduction at the duodenal brush border, so absorption is lower and more variable than ferrous sulphate; oral dosage forms are not interchangeable with equivalent elemental iron doses of ferrous salts without bioequivalence data. The finished tablets receive a polyvinyl alcohol-based moisture barrier film coat and are packed in aluminium/aluminium blisters with desiccant.

Hard Capsule Filling Requires a Low-Moisture Powder Blend

Capsule filling of ferric derisomaltose is constrained by the moisture affinity of the iron–carbohydrate complex. Powder blends are dried to a loss on drying not more than 2.0% before filling. Hard gelatin capsules require ambient humidity below 15% to prevent shell brittleness; hypromellose capsules are used when lower moisture protection is required. Fill weight is calculated from iron assay rather than total blend weight. Powder blends are densified in a low-shear tumble blender or roller compactor to improve flow. A tamping pin filling machine operates with pin settings adjusted to produce fill weight relative standard deviation not greater than 4%. Filled capsules are tested for content uniformity per USP <905> or Ph. Eur. 2.9.40. Dissolution testing uses 0.1 N hydrochloric acid as the acid stage medium; ferric iron release from the carbohydrate complex is pH-dependent and dissolution may be slower than ferrous salt products. No pharmacopoeial dissolution monograph exists for ferric derisomaltose capsules; acceptance criteria are established in the marketing authorisation dossier. Batch release includes microbial examination by USP <61> and USP <62>. The terminal packaged configuration is a polypropylene container with silica gel desiccant. Printing ink for capsule shells is selected to avoid elemental iron contamination under ICH Q3D.

If a sachet or sprinkle dosage form is required for patients who cannot swallow intact tablets, high-shear wet granulation is used with purified water or a neutral binder solution. Acidic binders are avoided because low pH can liberate ferric iron from the carbohydrate matrix. The granulator bowl is operated at impeller speed 200–400 rpm and chopper speed 1500–3000 rpm for 3–6 minutes. The wet mass is passed through a 1.0 mm or 1.5 mm screen. Fluid-bed drying is conducted with inlet air temperature 50–60°C and product temperature below 40°C to avoid thermodegradation of the complex. Target residual moisture is 1.5–2.5%. Dried granules are sieved; the fraction between 125 µm and 710 µm is used for sachet filling. Flowability is verified by pharmacopoeial methods; an angle of repose below 35° is considered acceptable for high-speed vertical form-fill-seal equipment. Each sachet contains a single dose equivalent to elemental iron; fill weight is controlled by gravimetric checkweigher to ±2%. Dispersion in water is tested by USP <701> or a dispersibility test for granules. Finished sachets are packed in aluminium foil laminate to exclude moisture. Published data specific to ferric derisomaltose oral granules is limited; these parameters are process targets requiring product-specific validation.

What Changes When a Hospital Pharmacy Prepares Sterile Admixtures from Single-Dose Vials?

Centralised intravenous admixture preparation transfers ferric derisomaltose from the manufacturer’s vial into infusion bags. Aseptic technique is performed in an ISO 5 laminar airflow workbench within an ISO 7 buffer room as defined by USP <797>. The vial top is disinfected with sterile 70% isopropyl alcohol and allowed to dry. A vented spike or closed system transfer device is used to avoid coring and reduce contaminant transfer. The dose is added to 100 mL or 250 mL of 0.9% sodium chloride injection. Bags are labelled with the beyond-use date; in the absence of manufacturer stability data, the beyond-use date is assigned according to the current USP <797> category based on the compounding environment and starting components. Admixtures are visually inspected for precipitation; free iron release can produce brown discoloration. Infusion is administered through a 15 µm in-line filter where filtration is used; this retains particulate matter without retaining the colloidal active fraction. No mixing with other medicinal products is permitted in the same bag. Residual drug from partially used vials is discarded according to single-dose vial policy. Barcode verification and gravimetric checking reduce dose errors.

When a Paediatric Dose Requires Weight-Based Dilution below the Registered Single-Dose Strength

If paediatric use requires a dose lower than the full vial, weight-based withdrawal is performed using the elemental iron concentration per millilitre. Dosing is calculated from elemental iron per kilogram body weight; the approved prescribing information defines the maximum single dose and minimum haemoglobin thresholds. A 1 mL or 3 mL Luer-lock syringe with graduations not more than 0.1 mL is used for volumetric accuracy. The withdrawn volume is transferred to a syringe pump for slow infusion. Residual air is minimised because the colloidal complex can form foam during syringe preparation. The infusion line is primed with sodium chloride before connection to avoid bolus dosing. Patients are monitored for hypersensitivity symptoms during the first 30 minutes of infusion. Dose rounding is performed according to institutional paediatric protocols. Polyvinyl chloride-free tubing is used where required by regional labelling. Any unused portion is discarded; vials are single-dose and do not contain antimicrobial preservatives. The terminal infusion remains a parenteral product, so particulate and sterility requirements continue to apply after compounding.

Pharmacopoeial Monograph Alignment for Injectable and Oral-Grade Release

Batch release of ferric derisomaltose API for injectable and oral applications follows different risk profiles. Injectable grade is tested for bacterial endotoxins by USP <85> or Ph. Eur. 2.6.14. Sterility of the finished injection is confirmed by USP <71> or Ph. Eur. 2.6.1. Elemental impurities are controlled under ICH Q3D using parenteral permitted daily exposure values; arsenic, cadmium, lead, and mercury limits are tested by USP <233>. Residual solvents are controlled under ICH Q3C. The API specification includes total iron and free iron, molecular weight distribution, pH, and particulate matter. For oral grade, endotoxin and sterility requirements are reduced, but microbial examination under USP <61> and USP <62> applies. Iron release from oral dosage forms is measured by pharmacopoeial atomic absorption or inductively coupled plasma methods. Ferric derisomaltose contains no dextran; the carbohydrate component consists of maltose and isomaltose oligosaccharides, which is relevant to injectable iron safety because dextran-derived anaphylactic markers are not present. The following compliance matrix summarises the main release and finished product tests.